Nkarta, Inc. financial data

Symbol
NKTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1150 Veterans Boulevard, South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.29 K % -25%
Debt-to-equity 31.5 % +21.4%
Return On Equity -34.1 % -10.7%
Return On Assets -26 % -6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.4 M shares +1%
Common Stock, Shares, Outstanding 49.2 M shares +0.62%
Entity Public Float 38.4 M USD -88.9%
Common Stock, Value, Issued 7 K USD +40%
Weighted Average Number of Shares Outstanding, Basic 50.7 M shares +3.6%
Weighted Average Number of Shares Outstanding, Diluted 50.7 M shares +3.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 95.9 M USD -1.63%
General and Administrative Expense 34.2 M USD +15.2%
Operating Income (Loss) -130 M USD -2.3%
Nonoperating Income (Expense) 13.9 M USD +63.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -116 M USD +2.07%
Earnings Per Share, Basic -2.35 USD/shares +4.08%
Earnings Per Share, Diluted -2.35 USD/shares +4.08%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 250 M USD +366%
Other Assets, Current 1.62 M USD -44.7%
Assets, Current 443 M USD +33.3%
Property, Plant and Equipment, Net 78.5 M USD +12.5%
Operating Lease, Right-of-Use Asset 39.4 M USD -13.6%
Other Assets, Noncurrent 3.72 M USD +98.9%
Assets 577 M USD +25.9%
Accounts Payable, Current 3.18 M USD -41.3%
Employee-related Liabilities, Current 3.77 M USD +0.16%
Accrued Liabilities, Current 12.9 M USD -12.7%
Liabilities, Current 22.2 M USD -14.6%
Operating Lease, Liability, Noncurrent 81.1 M USD -5.2%
Other Liabilities, Noncurrent 5 K USD -91.1%
Liabilities 103 M USD -7.39%
Accumulated Other Comprehensive Income (Loss), Net of Tax -127 K USD +27%
Retained Earnings (Accumulated Deficit) -465 M USD -33.3%
Stockholders' Equity Attributable to Parent 474 M USD +36.6%
Liabilities and Equity 577 M USD +25.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.5 M USD -37.3%
Net Cash Provided by (Used in) Financing Activities 226 M USD +22626500%
Net Cash Provided by (Used in) Investing Activities 21.5 M USD -41.8%
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 49.2 M shares +0.62%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 219 M USD +1256%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 253 M USD +349%
Deferred Tax Assets, Valuation Allowance 102 M USD +43.2%
Deferred Tax Assets, Gross 118 M USD +31%
Operating Lease, Liability 87.2 M USD -4.51%
Payments to Acquire Property, Plant, and Equipment 175 K USD -96.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -116 M USD +1.76%
Lessee, Operating Lease, Liability, to be Paid 137 M USD -8.49%
Property, Plant and Equipment, Gross 92.5 M USD +21%
Operating Lease, Liability, Current 6.08 M USD +5.67%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.5 M USD +3.29%
Lessee, Operating Lease, Liability, to be Paid, Year One 13 M USD +1.59%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 50 M USD -14.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13.9 M USD +3.3%
Deferred Tax Assets, Operating Loss Carryforwards 43.5 M USD +18.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 54.4 M shares 0%
Unrecognized Tax Benefits 3.74 M USD +59.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 14.4 M USD +3.31%
Operating Lease, Payments 3.3 M USD -43.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 7.4 M USD +164%
Deferred Tax Assets, Net of Valuation Allowance 16.3 M USD -14.7%
Share-based Payment Arrangement, Expense 16.8 M USD -3.91%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%